Placebo News and Research

RSS

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Researchers have shown that the glucose-lowering drug liraglutide safely and effectively decreases the overall risk of heart attack, stroke, or cardiovascular death for people with type 2 diabetes.

14 Jun 2016

Screening PSA levels in younger men could accurately predict future risk of prostate cancer

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk.

14 Jun 2016

Age no barrier to vorapaxar use in ACS

The protease-activated receptor 1 inhibitor vorapaxar offers the same benefits to older and younger patients with non-ST segment elevation acute coronary syndromes, shows further analysis of the TRACER trial.

14 Jun 2016

Blue wavelength light exposure leads to subsequent increases in brain activity in prefrontal cortex

A new study found that blue wavelength light exposure led to subsequent increases in brain activity in the dorsolateral prefrontal cortex (DLPFC) and the ventrolateral prefrontal cortex (VLPFC) when participants were engaging in a cognitive task after cessation of light exposure.

13 Jun 2016

Diabetes-heart disease combination can increase death risk

The combination of type 2 diabetes and coronary artery disease can be deadly. New research from a global study led by a physician from UConn Health has found that patients with Type 2 diabetes admitted into the hospital for congestive heart failure face a one in four chance of dying over the next 18 months.

13 Jun 2016

FDA approves Vaxchora for prevention of cholera

The U.S. Food and Drug Administration today approved Vaxchora, a vaccine for the prevention of cholera caused by serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas. Vaxchora is the only FDA-approved vaccine for the prevention of cholera.

13 Jun 2016

Liraglutide enhances high-dose insulin treatment in Type 2 diabetes

The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.

12 Jun 2016

New drug ixekizumab helps clear severe psoriasis symptoms

About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine.

10 Jun 2016

New drug for chronic migraine may reduce headache hours in few days

A new drug to prevent migraine was associated with fewer headache hours for people with chronic migraine within three to seven days after the first injection, according to a study published in the June 8, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2016

Most antidepressants are ineffective at treating children and teens, study shows

The majority of antidepressants prescribed to treat children and teenagers with major depression are ineffective and may even be unsafe, warn researchers.

9 Jun 2016

Migraine drug has quick onset of action

The drug TEV-48125, shown to be effective for chronic migraine in a phase II trial, appears to work within 3 to 7 days of injection, researchers report.

9 Jun 2016

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Empagliflozin has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

6 Jun 2016

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival.

6 Jun 2016

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

Salsalate has no greater effect than placebo on the progression of coronary artery plaque, show the findings of the randomised TINSAL-CVD trial.

3 Jun 2016

Alcoholic individuals may form stronger memory associations with alcohol-related environmental stimuli

Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.

2 Jun 2016

$CD34+ cell therapy improves angina frequency in no option patients with class III/IV angina refractory$

CD34+ cell therapy improves angina frequency in no option patients with class III/IV angina refractory

A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34 -- a member of a family of proteins that have an impact on vascular-associated tissue -- cells had a significant reduction in angina frequency over patients who received placebo.

2 Jun 2016

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.

1 Jun 2016

Placebo News and Research

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Screening PSA levels in younger men could accurately predict future risk of prostate cancer

Age no barrier to vorapaxar use in ACS

Blue wavelength light exposure leads to subsequent increases in brain activity in prefrontal cortex

Diabetes-heart disease combination can increase death risk

FDA approves Vaxchora for prevention of cholera

Liraglutide enhances high-dose insulin treatment in Type 2 diabetes

New drug ixekizumab helps clear severe psoriasis symptoms

New drug for chronic migraine may reduce headache hours in few days

Most antidepressants are ineffective at treating children and teens, study shows

Migraine drug has quick onset of action

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

Alcoholic individuals may form stronger memory associations with alcohol-related environmental stimuli

CD34+ cell therapy improves angina frequency in no option patients with class III/IV angina refractory

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

Additional drug treatment options to prevent migraine may offer hope to sufferers

Betrixaban scores near miss for extended thromboprophylaxis

Oncologists to present latest research findings at ASCO annual meeting

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News